Moreover, some patients suffering from BRAF-mutated melanoma and treated with anti-BRAF compounds exhibit resistance to the treatment by reactivation of the MEK/ERK pathway through MAP3K8/TPL-2/COT accumulation14, 17. This evidence concerns the gene MAP3K8 and melanoma.